Swiss startup Atlas Bio secures $12.5M to tackle drug development’s 70% failure rate and move beyond animal testing

Swiss tech-bio firm Atlas Bio today launched from stealth with a $10 million Seed round led by Creandum , alongside a previously unannounced pre-Seed round led by First Momentum Ventures and LEA Partners, bringing its total funding to $12.5 million. Atlas Bio is developing a foundational AI model to run in silico clinical trials. By simulating patient-level efficacy and safety signals before Phase II, Atlas Bio aims to de-risk clinical development, improve trial design, and support the industry’